1.1. Aims: Thymidine kinase 1(TK1) is a precision protein molecular target for assessment of tumor proliferating rate. This investigation of 3 cases are whether the elevated STK1p after the 2-cycle -chemotherapy associated with failure poor survival of clinical stage I-II in non-small-cell lung carcinomas (NSCLCs).
1.2. Main Methods: The 3 post- operative NSCLCs with clinical stage 1-II were confirmed by pathology and followed by individual chemotherapy. The serum thymidine kinase 1 protein (STK1p) was measured using the ECL dot blot assay.